13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001589122
Total reported value
$401.5M
$401.5M
3 檔
1472.6%
The Q3 2025 SEC filing reveals that Exor N.V. held a total portfolio value of $401.5M, covering 3 public equity positions.
In Q3 2025, Exor N.V. displayed an active expansion posture, initiating 1 new positions and adding to 1 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including IKENA ONCOLOGY INC, VIA, CLVT) accounted for 1472.6% of total reported equity market value during Q3 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ✓ | Ikena Oncology Inc | Stock-Other | 84.16% | -92.90% | EXIT | |
| 2 | VIA | Via Transportation Inc-cl A | Stock-Other | 11.48% | +59.87% | — | |
| 3 | CLVT | Clarivate Plc | Stock-Other | 4.36% | +33.04% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CLVT | Clarivate Plc | -1.3% | — | Unchanged |
| 2 | ✓ | Ikena Oncology Inc | -10.2% | — | Add |
| 3 | VIA | Via Transportation Inc-cl A | — | NEW | New buy |
According to official SEC Form 13F filings, Exor N.V. reported a total U.S. public equity portfolio value of $401.5M across 3 disclosed positions in Q3 2025.
During Q3 2025, Exor N.V.'s top holdings by market value included IKENA ONCOLOGY INC (84.2%)、VIA (11.5%)、CLVT (4.4%). The largest single position, IKENA ONCOLOGY INC, represented 84.2% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
VIA
市值: $678.9M
In Q3 2025, Exor N.V. made 2 total portfolio adjustments, initiating 1 new buys, adding to 1 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.